Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Minority Interest: 2014-2018

Historic Minority Interest for Coherus Oncology (CHRS) over the last 3 years, with Jun 2018 value amounting to -$1.3 million.

  • Coherus Oncology's Minority Interest fell 4.52% to -$1.3 million in Q2 2018 from the same period last year, while for Jun 2018 it was -$1.3 million, marking a year-over-year decrease of 4.52%. This contributed to the annual value of -$1.3 million for FY2017, which is 9.89% down from last year.
  • According to the latest figures from Q2 2018, Coherus Oncology's Minority Interest is -$1.3 million, which was down 3.63% from -$1.3 million recorded in Q1 2018.
  • In the past 5 years, Coherus Oncology's Minority Interest ranged from a high of -$44,000 in Q4 2014 and a low of -$1.3 million during Q2 2018.
  • Its 3-year average for Minority Interest is -$1.2 million, with a median of -$1.2 million in 2017.
  • Data for Coherus Oncology's Minority Interest shows a maximum YoY slumped of 1,540.91% (in 2015) over the last 5 years.
  • Coherus Oncology's Minority Interest (Quarterly) stood at -$44,000 in 2014, then tumbled by 1,540.91% to -$722,000 in 2015, then tumbled by 62.47% to -$1.2 million in 2016, then fell by 9.89% to -$1.3 million in 2017, then decreased by 4.52% to -$1.3 million in 2018.
  • Its Minority Interest stands at -$1.3 million for Q2 2018, versus -$1.3 million for Q1 2018 and -$1.3 million for Q4 2017.